Vivek Makwana

558 total citations
10 papers, 436 citations indexed

About

Vivek Makwana is a scholar working on Molecular Biology, Organic Chemistry and Biomaterials. According to data from OpenAlex, Vivek Makwana has authored 10 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Organic Chemistry and 2 papers in Biomaterials. Recurrent topics in Vivek Makwana's work include Glycosylation and Glycoproteins Research (5 papers), Carbohydrate Chemistry and Synthesis (3 papers) and Galectins and Cancer Biology (2 papers). Vivek Makwana is often cited by papers focused on Glycosylation and Glycoproteins Research (5 papers), Carbohydrate Chemistry and Synthesis (3 papers) and Galectins and Cancer Biology (2 papers). Vivek Makwana collaborates with scholars based in Australia and India. Vivek Makwana's co-authors include Santosh Rudrawar, Rashmi Jain, Amita Joshi, Manish Nivsarkar, Shailendra Anoopkumar‐Dukie, Philip Ryan, Thomas Haselhorst, Michael Kassiou, Andrew K. Davey and Tristan A. Reekie and has published in prestigious journals such as International Journal of Pharmaceutics, Biochimica et Biophysica Acta (BBA) - General Subjects and European Journal of Medicinal Chemistry.

In The Last Decade

Vivek Makwana

9 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vivek Makwana Australia	8	235	104	85	59	58	10	436
Abderrazzak Bentaher France	11	156 0.7×	46 0.4×	65 0.8×	63 1.1×	49 0.8×	22	514
Anindita De India	11	241 1.0×	127 1.2×	100 1.2×	26 0.4×	21 0.4×	22	447
Kalyani Mondal India	16	421 1.8×	32 0.3×	62 0.7×	85 1.4×	29 0.5×	32	749
Sudhanshu Sharma India	11	129 0.5×	57 0.5×	34 0.4×	15 0.3×	37 0.6×	31	416
Yongxiang Zheng China	11	228 1.0×	25 0.2×	53 0.6×	21 0.4×	56 1.0×	34	426
Yumei Wu China	9	167 0.7×	193 1.9×	112 1.3×	12 0.2×	23 0.4×	16	497
Shaimaa K. Mostafa Egypt	4	106 0.5×	63 0.6×	143 1.7×	12 0.2×	40 0.7×	6	376
Kuan-Boone Tan Singapore	8	218 0.9×	35 0.3×	117 1.4×	15 0.3×	17 0.3×	10	397
J.D. Pipkin United States	16	175 0.7×	209 2.0×	39 0.5×	32 0.5×	58 1.0×	34	529

Countries citing papers authored by Vivek Makwana

Since Specialization

Citations

This map shows the geographic impact of Vivek Makwana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Makwana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Makwana more than expected).

Fields of papers citing papers by Vivek Makwana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek Makwana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Makwana. The network helps show where Vivek Makwana may publish in the future.

Co-authorship network of co-authors of Vivek Makwana

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Makwana. A scholar is included among the top collaborators of Vivek Makwana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Makwana. Vivek Makwana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Makwana, Vivek, et al.. (2024). Bisubstrate Uridine‐Mimetic‐Peptide Conjugates as O ‐GlcNAc Transferase (OGT) Inhibitors. ChemistrySelect. 9(7). 2 indexed citations

Makwana, Vivek, Santosh Rudrawar, & Shailendra Anoopkumar‐Dukie. (2021). Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867(7). 166129–166129. 18 indexed citations

Makwana, Vivek, et al.. (2020). Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. International Journal of Pharmaceutics. 593. 120117–120117. 100 indexed citations

Makwana, Vivek, et al.. (2020). Investigating the Impact of OGT Inhibition on Doxorubicin- and Docetaxel-Induced Cytotoxicity in PC-3 and WPMY-1 Cells. International Journal of Toxicology. 39(6). 586–593. 17 indexed citations

Makwana, Vivek, et al.. (2020). Leptanoine D, a New Quinoline Alkaloid from the Australian Tree Pitaviaster haplophyllus (Rutaceae). Australian Journal of Chemistry. 74(3). 173–178.

Makwana, Vivek, Philip Ryan, Alpeshkumar K. Malde, Shailendra Anoopkumar‐Dukie, & Santosh Rudrawar. (2020). Bisubstrate Ether‐Linked Uridine‐Peptide Conjugates as O‐GlcNAc Transferase Inhibitors. ChemMedChem. 16(3). 477–483. 8 indexed citations

Makwana, Vivek, et al.. (2019). Essential role of O-GlcNAcylation in stabilization of oncogenic factors. Biochimica et Biophysica Acta (BBA) - General Subjects. 1863(8). 1302–1317. 42 indexed citations

Ryan, Philip, et al.. (2019). Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY. European Journal of Medicinal Chemistry. 171. 462–474. 20 indexed citations

Ryan, Philip, Vivek Makwana, Hemant R. Jadhav, et al.. (2018). Peptides, Peptidomimetics, and Carbohydrate–Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer’s Disease. ACS Chemical Neuroscience. 9(7). 1530–1551. 82 indexed citations

10.

Makwana, Vivek, et al.. (2015). Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. International Journal of Pharmaceutics. 495(1). 439–446. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact